CN1152049C - 用生长激素促分泌素治疗胰岛素抗性 - Google Patents

用生长激素促分泌素治疗胰岛素抗性 Download PDF

Info

Publication number
CN1152049C
CN1152049C CNB988059231A CN98805923A CN1152049C CN 1152049 C CN1152049 C CN 1152049C CN B988059231 A CNB988059231 A CN B988059231A CN 98805923 A CN98805923 A CN 98805923A CN 1152049 C CN1152049 C CN 1152049C
Authority
CN
China
Prior art keywords
oxo
general formula
compound
ethyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988059231A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259140A (zh
Inventor
P��A����Ƥŵ
P·A·卡皮诺
�����桤����
C·国锋·赵
�����շ�������˹��
B·A·勒夫克
L·C·潘
J·L·特勒拉德瓦
M·P·萨威斯托斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1259140A publication Critical patent/CN1259140A/zh
Application granted granted Critical
Publication of CN1152049C publication Critical patent/CN1152049C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988059231A 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性 Expired - Fee Related CN1152049C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25
US60/050,790 1997-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100334189A Division CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Publications (2)

Publication Number Publication Date
CN1259140A CN1259140A (zh) 2000-07-05
CN1152049C true CN1152049C (zh) 2004-06-02

Family

ID=21967444

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988059231A Expired - Fee Related CN1152049C (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性
CNA2004100334189A Pending CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100334189A Pending CN1530107A (zh) 1997-06-25 1998-06-05 用生长激素促分泌素治疗胰岛素抗性

Country Status (40)

Country Link
US (3) US6448263B1 (enExample)
EP (1) EP1000085B1 (enExample)
JP (2) JP2000514099A (enExample)
KR (1) KR20010014224A (enExample)
CN (2) CN1152049C (enExample)
AP (1) AP1145A (enExample)
AR (1) AR012256A1 (enExample)
AT (1) ATE305477T1 (enExample)
AU (1) AU747510B2 (enExample)
BG (1) BG104008A (enExample)
BR (1) BR9810477A (enExample)
CA (1) CA2294464A1 (enExample)
CO (1) CO4950621A1 (enExample)
DE (1) DE69831745T2 (enExample)
DZ (1) DZ2539A1 (enExample)
EA (1) EA002089B1 (enExample)
EG (1) EG21712A (enExample)
ES (1) ES2248899T3 (enExample)
HN (1) HN1998000088A (enExample)
HR (1) HRP980361A2 (enExample)
HU (1) HUP0001922A3 (enExample)
ID (1) ID24345A (enExample)
IL (7) IL154112A0 (enExample)
IN (1) IN189724B (enExample)
IS (1) IS5275A (enExample)
MA (1) MA24581A1 (enExample)
NO (1) NO996205L (enExample)
NZ (1) NZ500655A (enExample)
OA (1) OA11242A (enExample)
PA (1) PA8452601A1 (enExample)
PE (1) PE105399A1 (enExample)
PL (1) PL337659A1 (enExample)
SK (1) SK175699A3 (enExample)
TN (1) TNSN98113A1 (enExample)
TR (1) TR199903257T2 (enExample)
TW (1) TW553943B (enExample)
UA (1) UA64751C2 (enExample)
WO (1) WO1998058949A1 (enExample)
YU (1) YU70199A (enExample)
ZA (1) ZA985546B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006068964A2 (en) * 2004-12-21 2006-06-29 Hercules Incorporated Reactive cationic resins for use as dry and wet strength agents in sulfite ion-containing papermaking systems
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US9873695B2 (en) * 2014-08-05 2018-01-23 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
WO2016067638A1 (en) * 2014-10-31 2016-05-06 Raqualia Pharma Inc. Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
WO1994011012A1 (en) 1992-11-06 1994-05-26 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
NZ258412A (en) 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
AU715856B2 (en) 1995-12-22 2000-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
ATE356139T1 (de) * 1997-06-25 2007-03-15 Pfizer Dipeptidderivate zur förderung der sekretion von wachstumshormon

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164129A (zh) * 2013-05-28 2015-12-16 拉夸里亚创药株式会社 多晶型物形式
US9499543B2 (en) 2013-05-28 2016-11-22 Raqualia Pharma Inc. Polymorph forms
CN105164129B (zh) * 2013-05-28 2018-01-19 拉夸里亚创药株式会社 多晶型物形式

Also Published As

Publication number Publication date
IL156465A (en) 2004-07-25
IL156465A0 (en) 2004-01-04
JP2005097261A (ja) 2005-04-14
OA11242A (en) 2003-07-23
US6867202B1 (en) 2005-03-15
IL154114A0 (en) 2003-07-31
TR199903257T2 (xx) 2000-12-21
AU7445698A (en) 1999-01-04
HUP0001922A3 (en) 2001-02-28
DE69831745D1 (de) 2006-02-09
ES2248899T3 (es) 2006-03-16
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
AP9801267A0 (en) 1998-06-30
IL154116A0 (en) 2003-07-31
US6448263B1 (en) 2002-09-10
PE105399A1 (es) 1999-11-04
TW553943B (en) 2003-09-21
US20030100561A1 (en) 2003-05-29
EG21712A (en) 2002-02-27
EP1000085A1 (en) 2000-05-17
SK175699A3 (en) 2001-04-09
WO1998058949A1 (en) 1998-12-30
HN1998000088A (es) 1999-01-08
PA8452601A1 (es) 2000-05-24
AP1145A (en) 2003-02-14
DZ2539A1 (fr) 2003-02-08
BR9810477A (pt) 2007-05-22
JP3742643B2 (ja) 2006-02-08
US6630487B2 (en) 2003-10-07
DE69831745T2 (de) 2006-08-31
NZ500655A (en) 2002-02-01
ZA985546B (en) 2000-01-10
TNSN98113A1 (fr) 2005-03-15
EP1000085B1 (en) 2005-09-28
HRP980361A2 (en) 1999-02-28
ID24345A (id) 2000-07-13
CA2294464A1 (en) 1998-12-30
UA64751C2 (uk) 2004-03-15
NO996205D0 (no) 1999-12-15
IL154111A0 (en) 2003-07-31
KR20010014224A (ko) 2001-02-26
NO996205L (no) 1999-12-15
JP2000514099A (ja) 2000-10-24
HK1028051A1 (en) 2001-02-02
IS5275A (is) 1999-11-26
CO4950621A1 (es) 2000-09-01
CN1259140A (zh) 2000-07-05
IL154115A0 (en) 2003-07-31
ATE305477T1 (de) 2005-10-15
IL133626A0 (en) 2001-04-30
PL337659A1 (en) 2000-08-28
AR012256A1 (es) 2000-09-27
EA199901075A1 (ru) 2000-08-28
CN1530107A (zh) 2004-09-22
MA24581A1 (fr) 1998-12-31
IN189724B (enExample) 2003-04-19
BG104008A (en) 2000-07-31
AU747510B2 (en) 2002-05-16
YU70199A (sh) 2003-01-31
EA002089B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
CN1152049C (zh) 用生长激素促分泌素治疗胰岛素抗性
CN1113895C (zh) 生长激素促分泌素
CN1045595C (zh) 合成3－氨基哌啶衍生物的中间体的制备方法
CN1036590C (zh) 新的巯基乙酰基酰胺衍生物的制备方法
CN1224623C (zh) 1－苯基磺酰基－1,3－二氢－2h－吲哚－2－酮衍生物,其制备及其治疗应用
CN1633297A (zh) 作为黑皮质素－4受体激动剂的酰化哌啶衍生物
CN1688583A (zh) 用作治疗醛固酮介导的病症的药物的有机化合物
CN1232507C (zh) 生长激素促分泌剂
CN1842526A (zh) 苯并二氮杂䓬cgrp受体拮抗剂
CN1142911C (zh) 具有释放生长激素特性的化合物
CN1901908A (zh) 治疗性化合物及其用途
CN87101164A (zh) 次膦酸衍生物
CN1143647A (zh) 促进生长激素释放的二肽
CN1802369A (zh) Cgrp受体拮抗剂
CN1288464A (zh) 作为orl－1受体激动剂的4－(2－酮－1－苯并咪唑啉基)哌啶化合物
CN1625558A (zh) 氮杂－芳基哌嗪类化合物
CN1812982A (zh) 苯并二氮杂䓬cgrp受体拮抗剂
CN1826116A (zh) 作为黑皮素－4受体激动剂的哌啶衍生物
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1097192A (zh) 逆转录酶病毒蛋白酶抑制剂
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN101068595A (zh) Cgrp受体拮抗剂
CN1780820A (zh) 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物
CN1410059A (zh) 治疗方法和包含促生长激素分泌剂的药盒
CN1157224C (zh) 用作生长激素促分泌剂的新酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee